Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer

1 Apr 2018

Abstract excerpt

CDK4/6 inhibitors are effective against cancer cells expressing the tumor suppressor RB1, but not RB1-deficient cells, posing the challenge of how to target RB1 loss. In triple-negative breast cancer (TNBC), RB1 and PTEN are frequently inactivated together with TP53. We performed kinome/phosphatase inhibitor screens on primary mouse Rb/p53-, Pten/p53-, and human RB1/PTEN/TP53-deficient TNBC cell lines and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29617654
DOI: 10.1016/j.celrep.2018.03.039

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast CancerPMID 29617654Read ↗

In Vivo Roles of CDC25 Phosphatases: Biological Insight into the Anti-Cancer Therapeutic TargetsSemantic proximity Read ↗

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancerSemantic proximity Read ↗

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoverySemantic proximity Read ↗

CDC25A Phosphatase: a Rate-Limiting Oncogene That Determines Genomic StabilitySemantic proximity Read ↗

Cell Cycle Control by the CDC25 PhosphatasesSemantic proximity Read ↗

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast CancerSemantic proximity Read ↗

CDC25B induces cellular senescence and correlates with tumor suppression in a p53-dependent mannerSemantic proximity Read ↗

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell LinesSemantic proximity Read ↗

Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13Semantic proximity Read ↗

CDC73 promotes breast cancer through impairing MAPK1 ubiquitination and activating mTOR signaling pathwaySemantic proximity Read ↗

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.Semantic proximity Read ↗

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.